tirzepatide and naltrexone Pharmacological Management of Obesity According to ADA Standards of Care (Jan-Feb 2026), here are the latest medications for obesity treatment in adults with their mechanisms mean weight reduction: Dual GIP/GLP-1 Bupropion Naltrexone | Calosense Med

Semaglutide is a powerful weight loss tool, but patients with existing kidney disease need careful monitoring

Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks

The GLP-1 receptor agonist drug class has revolutionized obesity treatment, but key unmet needs persist

Fatigue is one of the most common complaints from people taking meds like Ozempic, Wegovy, and Mounjaro and its frustrating when youre hoping to feel healthier, not more exhausted

The possibility of hypoglycemia should also be considered, especially in patients receiving treatment for diabetes

Taylor is dedicated to helping adolescents and adults overcome addiction and co-occurring psychiatric disorders